Clearmind Medicine (CMND) said Tuesday it has completed dosing for all 24 participants in cohorts 1 through 4 of part A of its ongoing phase 1/II trial evaluating its experimental drug, CMND-100, for the treatment of alcohol use disorder.
The company said that all healthy participants in the first stage of the study received escalating dose levels of its proprietary drug candidate.
Clearmind said that clinical trial sites achieved rapid patient recruitment and efficient treatment timelines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments